-
2025-520979-13-00
5
2025-12-18
Patients with HR+ HER2- early breast cancer at intermediate risk of re
-
2025-521293-34-00
4
2025-12-09
Moderate-to-severe hidradenitis suppurativa
-
2025-521775-31-00
5
2025-11-12
Stage IB-IIIA NSCLC Patients with uncommon EGFR Mutations
-
2024-520107-12-00
5
2025-09-03
Hidradenitis Suppurativa // Prurigo Nodularis // Vitiligo
-
2024-517004-11-00
5
2024-10-22
Chronic pulmonary aspergillosis
-
2024-511404-17-00
5
2024-10-07
Unresectable or metastatic NRAS mutant cutaneous melanoma
-
2023-504670-38-00
4
2023-11-17
Extensive disease Small Cell Lung Cancer
-
2022-502548-12-00
5
2023-09-28
marginal zone lymphoma
-
2024-510635-21-00
5
2023-05-09
warm autoimmune haemolytic anaemia (wAIHA)
-
2024-511267-28-00
5
2021-02-17
B-cell malignancies
-
2024-519620-24-01
5
2026-06-01
ANCA-associated vasculitis
-
2025-523552-31-00
5
2026-05-07
Systemic Lupus Erythematosus
-
2024-519208-29-00
4
2026-04-02
Pleural mesothelioma
-
2024-514949-11-00
5
2026-03-18
Hypoxemic acute respiratory failure
-
2024-515948-23-00
5
2026-02-06
Advanced pulmonary or gastroenteropancreatic poorly differentiated neu
-
2023-508930-33-00
4
2026-01-30
Non-infectious active cryoglobulinemia vasculitis who are either refra
-
2023-505781-28-00
4
2026-01-20
Patients with Waldenstrom macroglobulinemia and have received at least
-
2024-518385-26-01
5
2025-12-18
Polymyalgia Rheumatica (PMR)
-
2024-516789-13-00
6
2025-12-15
Severe asthma
-
2024-519971-25-00
5
2025-12-03
Advanced MET exon 14 Mutated Non-Small Cell Lung Cancer
-
2024-517411-73-00
6
2025-11-12
Patient with medium or high risk for pneumococcal invasive infection
-
2024-517316-29-00
4
2025-11-07
Unresectable stage III Non-Small Cell Lung Cancer
-
2023-506843-40-00
5
2025-10-29
Mycobacterium xenopi pulmonary infection
-
2024-511871-13-00
6
2025-10-02
Postmenopausal osteoporosis